Who we are

Novavax is a global biotechnology company focusing on driving value via our proven recombinant nanoparticle and Matrix-M™ technology through partnerships and R&D. To do this, we are focused on four value drivers: executing on current partnerships, developing our late-stage assets, driving additional partnerships and deals through our technology, and building a robust early-stage pipeline.

Our leadership

Our team has unparalleled experience developing vaccines, conducting early proof-of-concept and clinical development work, and executing successful partnerships for further development and commercialization. Their immense depth of experience is ideally suited to exponentially increase the public health impact of our recombinant protein-based nanoparticle and Matrix-M™ adjuvant technology, while driving value for the Company.

Board of Directors